News stories about Zosano Pharma Corporation (NASDAQ:ZSAN) have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zosano Pharma Corporation earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.5797447361508 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Zosano Appoints Kenneth Greathouse to Board of Directors (feeds.benzinga.com)
- Average True Range Indicator can help out on Zosano Pharma Corporation (ZSAN) – Wall Street Morning (wallstreetmorning.com)
- Investors should Buy on Healthcare Stock: Zosano Pharma Corporation (ZSAN) – Street Observer (press release) (streetobserver.com)
- Zosano Provides Patent Application Update (finance.yahoo.com)
Shares of Zosano Pharma Corporation (NASDAQ:ZSAN) traded down 0.235% during trading on Friday, hitting $0.848. The stock had a trading volume of 169,274 shares. Zosano Pharma Corporation has a 12-month low of $0.45 and a 12-month high of $3.54. The stock has a 50-day moving average of $0.90 and a 200 day moving average of $0.90. The firm’s market cap is $33.27 million.
Zosano Pharma Corporation (NASDAQ:ZSAN) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). During the same quarter in the previous year, the firm earned ($0.54) earnings per share. On average, analysts predict that Zosano Pharma Corporation will post ($0.85) earnings per share for the current fiscal year.
Separately, ValuEngine cut Zosano Pharma Corporation from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Zosano Pharma Corporation (ZSAN) Stock Price” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/10/08/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-zosano-pharma-corporation-zsan-stock-price.html.
About Zosano Pharma Corporation
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.